Trial Condition(s):

Macular Edema

Special Drug Use Investigation of EYLEA for Diabetic Macular Edema

Bayer Identifier:

17544

ClinicalTrials.gov Identifier:

NCT02425501

EudraCT Number:

Not Available

Study Completed

Trial Purpose

The objectives of this study are to investigate the safety and effectiveness of EYLEA

Inclusion Criteria
- Patients who start EYLEA treatment for Diabetic Macular Edema (DME)
Exclusion Criteria
- Patients who have already received EYLEA treatment

Trial Summary

Enrollment Goal
646
Trial Dates
black-arrow
Phase
4
Could I receive a placebo?
No
Products
Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Investigative Site

Many Locations, Japan

Status
Completed
 

Trial Design